CRSP

Biotechnology CRSP TER TXG Uncategorized

Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics

Mar 11, 2026

Biotechnology CRSP Edmund Ingham NTLA Uncategorized VRTX

Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here’s My Take

Mar 9, 2026

BEAM Biotechnology CRSP NET PFE PFE:CA Robert J. Lake Uncategorized VRTX ZPFE:CA

Beam Therapeutics: Great Potential, But Patience Is Needed

Feb 27, 2026

APLS BBIO Biotechnology BMRN CRSP NTLA RARE RGNX Uncategorized

Rare disease pharmas could benefit from FDA guidance to accelerate development

Feb 23, 2026

Biotechnology CRSP Fundamental Options Uncategorized

Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward

Feb 19, 2026